SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

LexaGene Launches EUA Tests for Microfluidic PCR Device in Point-of-Care Facilities
LexaGene has begun a series of studies aimed to bring its MiQLab from research-only use to point-of-care use to detect the SARS-CoV-2 virus.
January 18, 2021
 · 
4 min read
 · 
Gail Dutton
Cell and Gene Therapies Shatter Prior Records, with Continued Growth Expected
Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM), painted a rosy picture despite a few challenges at the 2021 Cell & Gene State of the Industry Briefing during this year’s Biotech Showcase, held virtually January 11-15.
January 15, 2021
 · 
5 min read
 · 
Gail Dutton
Policy
Drug Prices Top of Mind as Pharma Leaders Consider Policies Under Biden
In many regards, the incoming Biden Administration is expected to be a redux of the Obama Administration, likely with strong support for scientific research and a reinvigoration of the Affordable Care Act. Yet concerns of pricing controls still loom.
January 14, 2021
 · 
5 min read
 · 
Gail Dutton
Drug Development
Adastra Pharma’s Novel Glioma Therapy Achieves Positive Phase Ib Outcomes
Adastra Pharmaceuticals’ positive results from a Phase Ib trial of its therapy for recurrent high-grade glioblastomas suggest an effective treatment could be available within the next several years.
January 13, 2021
 · 
4 min read
 · 
Gail Dutton
Business
BDO Report: Biotech CFOs, Optimistic for Recovery, Focus on Digital Transformation
Biotech CFOs, optimistic about economic recovery as COVID-19 vaccines role out, are busy digitally transforming their companies for a post-COVID way of working, according to the 2021 BDO Life Sciences CFO Outlook Survey, released January 11.
January 11, 2021
 · 
4 min read
 · 
Gail Dutton
Lone Star Bio
Regulating NIK Activity Emerges as New Way to Enhance Immuno-Oncology Therapies
Regulating the activity of the protein called NF-kappa B-inducing kinase (NIK) is emerging as a new and potentially important way to enhance certain immuno-oncology therapies.
January 11, 2021
 · 
3 min read
 · 
Gail Dutton
Drug Development
Chinook Applies Precision Medicine to Kidney Therapeutics for Rapid Advances
When Chinook Therapeutics looks at 2021, it foresees a host of clinical trials that will bring precision medicine to the kidney disease space.
January 8, 2021
 · 
3 min read
 · 
Gail Dutton
China Showcase 2021 Highlights Trends and Areas Ripe for Investment
Biotech growth in China continued at a rapid pace in 2020, despite COVID-19, which emerged from that country to become a global pandemic. Opportunities in China remain good and are expected to continue.
January 8, 2021
 · 
5 min read
 · 
Gail Dutton
Sven Kili_Vaticanconference2016, Bruce Levine_Cann
Obsidian Looks to 2021 Collabs as It Advances its Cell Therapy Platforms
In the run-up to January’s JP Morgan Healthcare Conference, BioSpace caught up with CEO Paul Wotton to discuss the company’s plans for 2021. More collaborations are key features.
January 7, 2021
 · 
4 min read
 · 
Gail Dutton
Genetown
Glympse Advances BioSensors for NASH and Other Protease-Mediated Diseases
Glympse Bio’s tunable biosensors are poised to be a game-changing diagnostic tool in 2021.
January 6, 2021
 · 
4 min read
 · 
Gail Dutton
Business
Cell Therapy Speed and Efficiency Driven by Draper’s New Way of Thinking
Draper, a not-for-profit research and development organization, is speeding the process with new tools designed specifically to produce cell therapies at scale.
January 5, 2021
 · 
4 min read
 · 
Gail Dutton
WUSTL Researchers ID Elusive Cause of Chiari 1 Brain Malformation
This news, published in the American Journal of Human Genetics, enables researchers to develop early screening methods before the most serious symptoms arise, and thus intervene.
January 4, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
COVID-19 Vaccines Are Safer Than COVID, Despite Adverse Events
A great deal remains unknown about the SARS-CoV-2 virus, its mutations, transmissibility and long-term effects. Here’s what we do know.
December 30, 2020
 · 
4 min read
 · 
Gail Dutton
Business
rBIO Launches with Technology to Hyper-Produce Insulin Cost-Effectively, at Scale
rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.
December 29, 2020
 · 
4 min read
 · 
Gail Dutton
Better Than MDA: PTA Whole Genome Amplification Has More Info, Fewer Errors
BioSkryb has developed a more robust technology for whole genome sequencing that accurately and uniformly captures more than 95% of the genomes of single cells.
December 21, 2020
 · 
5 min read
 · 
Gail Dutton
Load More